-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; ...

NEW YORK--(BUSINESS WIRE)--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...